Stan przedcukrzycowy a możliwości farmakoterapii Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 14, 2016
Słowa kluczowe:
nieprawidłowa glikemia na czczo, nieprawidłowa tolerancja glukozy, stan przedcukrzycowy, farmakoterapia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nieprawidłowa glikemia na czczo oraz nieprawidłowa tolerancja glukozy, wspólnie określane jako stan przedcukrzycowy, są związane z istotnym ryzykiem rozwoju cukrzycy. Przeprowadzone ostatnio badania dotyczące interwencji polegającej na modyfikacji stylu życia (dieta oraz wysiłek fizyczny) udowodniły skuteczność leczenia niefarmakologicznego w zapobieganiu cukrzycy u chorych ze stanem przedcukrzycowym. W artykule przedstawiono kryteria rozpoznania, zasady diagnostyki, epidemiologię zaburzeń węglowodanowych w Polsce oraz dowody naukowe dotyczące skuteczności farmakoterapii u chorych ze stanem przedcukrzycowym.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sobieraj , P., Kowalczyk , M., & Dęmbe , K. (2016). Stan przedcukrzycowy a możliwości farmakoterapii . Kardiologia W Praktyce, 10(3), 10-17. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1271
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Rutkowski M., Bandosz P., Czupryniak L. et al.: Prevalence of diabetes and impaired fasting glucose in Poland – the NATPOL 2011 Study. Diabet. Med. 2014; 31(12): 1568-1571.
2. International Diabetes Federation: IDF Diabetes Atlas – 7th Edition [online: http://www.diabetesatlasorg/across-the-globe.html].
3. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35(supl. 1): S64-S71.
4. Polskie Towarzystwo Diabetologiczne: Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016. Diab. Klin. 2016; 5(supl. A).
5. World Health Organization (WHO) IC: Definition and diagnosis of diabetes and intermediate hyperglycaemia. Online: http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/.
6. Mastalerz-Migas A., Pokorna-Kalwak D., Sapilak B.: The use of FINDRISC questionnaire in assessment of risk of the type 2 diabetes development in patients with hypertension. Atherosclerosis 2014; 235(2): e279.
7. American Diabetes Association: 4. Prevention or Delay of Type 2 Diabetes. Diabetes Care 2016; 39(supl. 1): S36-S38.
8. Abdul-Ghani M., DeFronzo R.A., Jayyousi A.: Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance: does it matter? Curr. Opin. Clin. Nutr. Metab. Care 2016 Jul 6 [Epub ahead of print].
9. Diabetes Prevention Program Research Group: The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet. Med. 2007; 24(2): 137-144.
10. Cheng Y.J., Gregg E.W., Geiss L.S. et al.: Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. Diabetes Care 2009; 32(11): 2027-2032.
11. Ziegler D., Rathmann W., Dickhaus T. et al.: Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008; 31(3): 464-469.
12. Decode Study Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26(3): 688-696.
13. Tuomilehto J., Lindstrom J., Eriksson J.G. et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001; 344(18): 1343-1350.
14. Penn L., White M., Oldroyd J. et al.: Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health 2009; 9: 342.
15. Roumen C., Corpeleijn E., Feskens E.J. et al.: Impact of 3-year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabet. Med. 2008; 25(5): 597-605.
16. Knowler W.C., Barrett-Connor E., Fowler S.E. et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346(6): 393-403.
17. Sussman J.B., Kent D.M., Nelson J.P., Hayward R.A.: Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ 2015; 350: h454.
18. Diabetes Prevention Program Research Group: Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003; 26(4): 977-980.
19. Perreault L., Pan Q., Mather K.J. et al.: Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012; 379(9833): 2243-2251.
20. Salpeter S.R., Buckley N.S., Kahn J.A., Salpeter E.E.: Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med. 2008; 121(2): 149-157.e2.
21. Chiasson J.L., Josse R.G., Gomis R. et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359(9323): 2072-2077.
22. Chiasson J.L.: Acarbose for type 2 diabetes prevention. Lancet 2002; 360(9344): 1517.
23. Scheen A.J.: Acarbose for type 2 diabetes prevention. Lancet 2002; 360(9344): 1516.
24. DeFronzo R.A., Tripathy D., Schwenke D.: Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 2011; 364: 1104-1115.
25. Espinoza S., Wang C., Tripathy D. et al.: Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. GeroScience 2016; 38: 485.
26. Kernan W.N., Viscoli C.M., Furie K.L. et al.: Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N. Engl. J. Med. 2016; 374(14): 1321-1331.
27. Origin Trial Investigators: Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 2012; 367(4): 319-328.
28. Torgerson J.S., Hauptman J., Boldrin M.N., Sjostrom L.: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1): 155-161.
29. European Society of Cardiology: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J. 2013; 34(39): 3035-3087.
30. NICE: Type 2 diabetes: prevention in people at high risk [online: www.nice.org.uk/guidance/ph38].
31. Alberti K.G., Zimmet P., Shaw J.: International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet. Med. 2007; 24(5): 451-463.
2. International Diabetes Federation: IDF Diabetes Atlas – 7th Edition [online: http://www.diabetesatlasorg/across-the-globe.html].
3. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35(supl. 1): S64-S71.
4. Polskie Towarzystwo Diabetologiczne: Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016. Diab. Klin. 2016; 5(supl. A).
5. World Health Organization (WHO) IC: Definition and diagnosis of diabetes and intermediate hyperglycaemia. Online: http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/.
6. Mastalerz-Migas A., Pokorna-Kalwak D., Sapilak B.: The use of FINDRISC questionnaire in assessment of risk of the type 2 diabetes development in patients with hypertension. Atherosclerosis 2014; 235(2): e279.
7. American Diabetes Association: 4. Prevention or Delay of Type 2 Diabetes. Diabetes Care 2016; 39(supl. 1): S36-S38.
8. Abdul-Ghani M., DeFronzo R.A., Jayyousi A.: Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance: does it matter? Curr. Opin. Clin. Nutr. Metab. Care 2016 Jul 6 [Epub ahead of print].
9. Diabetes Prevention Program Research Group: The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet. Med. 2007; 24(2): 137-144.
10. Cheng Y.J., Gregg E.W., Geiss L.S. et al.: Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. Diabetes Care 2009; 32(11): 2027-2032.
11. Ziegler D., Rathmann W., Dickhaus T. et al.: Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008; 31(3): 464-469.
12. Decode Study Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26(3): 688-696.
13. Tuomilehto J., Lindstrom J., Eriksson J.G. et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001; 344(18): 1343-1350.
14. Penn L., White M., Oldroyd J. et al.: Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health 2009; 9: 342.
15. Roumen C., Corpeleijn E., Feskens E.J. et al.: Impact of 3-year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabet. Med. 2008; 25(5): 597-605.
16. Knowler W.C., Barrett-Connor E., Fowler S.E. et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346(6): 393-403.
17. Sussman J.B., Kent D.M., Nelson J.P., Hayward R.A.: Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ 2015; 350: h454.
18. Diabetes Prevention Program Research Group: Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003; 26(4): 977-980.
19. Perreault L., Pan Q., Mather K.J. et al.: Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012; 379(9833): 2243-2251.
20. Salpeter S.R., Buckley N.S., Kahn J.A., Salpeter E.E.: Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med. 2008; 121(2): 149-157.e2.
21. Chiasson J.L., Josse R.G., Gomis R. et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359(9323): 2072-2077.
22. Chiasson J.L.: Acarbose for type 2 diabetes prevention. Lancet 2002; 360(9344): 1517.
23. Scheen A.J.: Acarbose for type 2 diabetes prevention. Lancet 2002; 360(9344): 1516.
24. DeFronzo R.A., Tripathy D., Schwenke D.: Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 2011; 364: 1104-1115.
25. Espinoza S., Wang C., Tripathy D. et al.: Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. GeroScience 2016; 38: 485.
26. Kernan W.N., Viscoli C.M., Furie K.L. et al.: Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N. Engl. J. Med. 2016; 374(14): 1321-1331.
27. Origin Trial Investigators: Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 2012; 367(4): 319-328.
28. Torgerson J.S., Hauptman J., Boldrin M.N., Sjostrom L.: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1): 155-161.
29. European Society of Cardiology: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J. 2013; 34(39): 3035-3087.
30. NICE: Type 2 diabetes: prevention in people at high risk [online: www.nice.org.uk/guidance/ph38].
31. Alberti K.G., Zimmet P., Shaw J.: International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet. Med. 2007; 24(5): 451-463.